Rifampisin Diren?li Mycobacterium tuberculosis Kompleks Su?lari zerine Benzimidazolyum Tuzlarinin Antimikobakteriyel Etkinli?inin Ara?tirilmasi

In this study, it was aimed to determine the antimycobacterial activity of 3 different compounds ((S1): 1-(N-methylphthalimide)-3benzylbenzimidazolium bromide, (S2): 1-(N-methylphthalimide)-3-(4methylbenzyl) benzimidazolium bromide, (S3): 1-(N-methylphthalimide)3-(naphthalen-1-ylmethyl) benzimidazolium bromide) containing benzimidazole nuclei on M. tuberculosis reference strain H37Rv and rifampicin resistant tuberculosis strains isolated from clinical samples sent to the Ministry of Health Adana Regional Tuberculosis Laboratory. Using the BACTEC MGIT 960 system, the antimycobacterial activity of benzimidazole derivative compounds were examined in vitro against M. tuberculosis H37Rv and 35 clinical strains of M. tuberculosis that were resistant to rifampicin. Furthermore, molecular docking was used to look into the possible interactions of the antimycobacterial compounds. According to the results of the study, compound S2 showed antimycobacterial activity against the M. tuberculosis H37Rv strain but it didn't have any effect on rifampicin-resistant M. tuberculosis strains. Compounds S1 and S3 didn't exhibit any antimycobacterial activity against both clinical and reference strains. The results of the molecular docking analysis revealed that S2 could bind to InhA and thus could exert its antimycobacterial activity by inhibiting it. As a result, the S2 compound can be suggested as a new agent for the treatment of tuberculosis, however, more comprehensive studies are needed.